Glaxosmithkline Plc (GSK) 48.68 $GSK
Drugmaker AstraZeneca Returns To Growth
at Investor's Business Daily - Tue Aug 05, 4:22PM CDT
British drugmaker AstraZeneca (AZN) has turned the corner after seeing its earnings fall for five straight quarters. In late July, the company delivered second-quarter earnings of $1.30 a share, up 8% from a year ago. Profit fell 17% to 28% in the...
GSK's COPD.com Relaunch Promotes Understanding and Dialogue about COPD
PR Newswire - Tue Aug 05, 8:00AM CDT
Today GlaxoSmithKline plc (LSE/NYSE: GSK) announced the launch of the redesigned COPD.com website, which provides disease education, interactive tools, tips and inspirational testimonials from patients living with chronic obstructive pulmonary disease (COPD), for an up-close and personal look at managing and living day-to-day with the condition.
Why GlaxoSmithKline (GSK) Stock Is Higher Today
at The Street - Mon Aug 04, 10:03AM CDT
Shares of GlaxoSmithKline (GSK) are up after Express Scripts (ESRX) reinstated the drug maker's top selling lung drug Advair as an approved drug in 2015.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Prosensa Holding N.V.
Business Wire - Mon Aug 04, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the ordinary shares of Prosensa Holding N.V. ("Prosensa" or the "Company"
(NASDAQ:RNA) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the "Registration Statement" issued in connection with the Company's initial public offering on or about June 28, 2013,have until September 16, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver
PR Newswire - Mon Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GRPN, GILD, BLDP, GSK, and LLY.
Closing for Pernix Transaction to Acquire Treximet(R) Tablets for Migraine from GSK Delayed
Business Wire - Mon Aug 04, 8:15AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company" , a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue.
Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.
Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
PR Newswire Europe - Thu Jul 31, 9:24AM CDT
DUBLIN, July 31, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/2qcxl8/global] has announced the addition of the "Global Parkinson's Disease Market 2014-2018" [http://www.researchandmarkets.com/research/2qcxl8/global] report to their offering.
Research and Markets: Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
Business Wire - Thu Jul 31, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq3zdg/global) has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering.
Why AstraZeneca (AZN) Stock Is Up Today
at The Street - Wed Jul 30, 6:56AM CDT
AstraZeneca (AZN) agreed to buy the rights to a portfolio of inhaled drugs from Almirall (LBTSF) in a deal worth up to $2.1 billion.
Chronic Plaque Psoriasis - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dpkjk3/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AbGenomics International, Inc. - AbbVie Inc. - Actelion Ltd - Almirall, S.A. - ApoPharma Inc. - Biotest AG - Boehringer Ingelheim GmbH - Can-Fite BioPharma Ltd. - Eli Lilly and Company - GlaxoSmithKline plc - Incyte Corporation - Merck & Co., Inc. - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/dp...nic_plaque
GSK's Tanzeum(TM) is now available in pharmacies in the U.S.
PR Newswire - Tue Jul 29, 2:31PM CDT
GSK (LSE/NYSE: GSK) today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.
Novartis Division Gets European Approval for Simbrinza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 5:30PM CDT
Novartis' (NVS) ophthalmology division, Alcon, received encouraging news when Simbrinza was approved by the European Commission.
What Makes Johnson & Johnson a Healthy Dividend Investment
at The Street - Mon Jul 28, 1:49PM CDT
Johnson & Johnson has a current dividend yield of $2.79 and earnings per share of $5.41.
MorphoSys AG Reports Results for the First Six Months of 2014
GlobeNewswire - Mon Jul 28, 12:09AM CDT
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). Reasons for the revenue decrease were one-time effects in H1 2013 such as a payment for a HuCAL license by Bio-Rad in connection with the sale of AbD Serotec and the license agreement with GlaxoSmithKline for MorphoSys's clinical antibody program MOR103. Earnings before interest and taxes (EBIT) from continued operations amounted to EUR 0.4 million (H1 2013: EUR 17.3 million). On 30 June 2014, MorphoSys's liquid funds, marketable securities and financial assets amounted to EUR 374.2 million (31 December 2013: EUR 390.7 million).
PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Johnson & Weaver, LLP Reminds Investors of Upcoming September 16, 2014 Deadline; Encourages Investors with Significant Losses to Contact the Firm
Business Wire - Sat Jul 26, 3:06PM CDT
Shareholder rights law firm Johnson & Weaver, LLP reminds investors of the September 16, 2014 lead plaintiff deadline in a securities class action lawsuit filed by the firm against Prosensa Holding N.V. (NASDAQ:RNA). The class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of the class (the "Class" . Those purchasers of the ordinary common shares of Prosensa pursuant and/or traceable to the Company's initial public offering ("IPO" on or about June 28, 2013 and suffered significant losses are encouraged to contact Johnson & Weaver regarding your legal rights.
Drugmaker AstraZeneca Returns To Growth
at Investor's Business Daily - Tue Aug 05, 4:22PM CDT
British drugmaker AstraZeneca (AZN) has turned the corner after seeing its earnings fall for five straight quarters. In late July, the company delivered second-quarter earnings of $1.30 a share, up 8% from a year ago. Profit fell 17% to 28% in the...
GSK's COPD.com Relaunch Promotes Understanding and Dialogue about COPD
PR Newswire - Tue Aug 05, 8:00AM CDT
Today GlaxoSmithKline plc (LSE/NYSE: GSK) announced the launch of the redesigned COPD.com website, which provides disease education, interactive tools, tips and inspirational testimonials from patients living with chronic obstructive pulmonary disease (COPD), for an up-close and personal look at managing and living day-to-day with the condition.
Why GlaxoSmithKline (GSK) Stock Is Higher Today
at The Street - Mon Aug 04, 10:03AM CDT
Shares of GlaxoSmithKline (GSK) are up after Express Scripts (ESRX) reinstated the drug maker's top selling lung drug Advair as an approved drug in 2015.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Prosensa Holding N.V.
Business Wire - Mon Aug 04, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the ordinary shares of Prosensa Holding N.V. ("Prosensa" or the "Company"
(NASDAQ:RNA) pursuant and/or traceable to the Registration Statement and Prospectus (collectively, the "Registration Statement" issued in connection with the Company's initial public offering on or about June 28, 2013,have until September 16, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver
PR Newswire - Mon Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GRPN, GILD, BLDP, GSK, and LLY.
Closing for Pernix Transaction to Acquire Treximet(R) Tablets for Migraine from GSK Delayed
Business Wire - Mon Aug 04, 8:15AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue. Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.
Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
PR Newswire Europe - Thu Jul 31, 9:24AM CDT
DUBLIN, July 31, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/2qcxl8/global] has announced the addition of the "Global Parkinson's Disease Market 2014-2018" [http://www.researchandmarkets.com/research/2qcxl8/global] report to their offering.
Research and Markets: Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
Business Wire - Thu Jul 31, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq3zdg/global) has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering.
Why AstraZeneca (AZN) Stock Is Up Today
at The Street - Wed Jul 30, 6:56AM CDT
AstraZeneca (AZN) agreed to buy the rights to a portfolio of inhaled drugs from Almirall (LBTSF) in a deal worth up to $2.1 billion.
Chronic Plaque Psoriasis - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dpkjk3/chronic_plaque) has announced the addition of the "Chronic Plaque Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - AbGenomics International, Inc. - AbbVie Inc. - Actelion Ltd - Almirall, S.A. - ApoPharma Inc. - Biotest AG - Boehringer Ingelheim GmbH - Can-Fite BioPharma Ltd. - Eli Lilly and Company - GlaxoSmithKline plc - Incyte Corporation - Merck & Co., Inc. - Novartis AG - OPKO Health, Inc. - Pfizer Inc. - Sandoz Inc. For more information visit http://www.researchandmarkets.com/research/dp...nic_plaque
GSK's Tanzeum(TM) is now available in pharmacies in the U.S.
PR Newswire - Tue Jul 29, 2:31PM CDT
GSK (LSE/NYSE: GSK) today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.
Novartis Division Gets European Approval for Simbrinza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 5:30PM CDT
Novartis' (NVS) ophthalmology division, Alcon, received encouraging news when Simbrinza was approved by the European Commission.
What Makes Johnson & Johnson a Healthy Dividend Investment
at The Street - Mon Jul 28, 1:49PM CDT
Johnson & Johnson has a current dividend yield of $2.79 and earnings per share of $5.41.
MorphoSys AG Reports Results for the First Six Months of 2014
GlobeNewswire - Mon Jul 28, 12:09AM CDT
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). Reasons for the revenue decrease were one-time effects in H1 2013 such as a payment for a HuCAL license by Bio-Rad in connection with the sale of AbD Serotec and the license agreement with GlaxoSmithKline for MorphoSys's clinical antibody program MOR103. Earnings before interest and taxes (EBIT) from continued operations amounted to EUR 0.4 million (H1 2013: EUR 17.3 million). On 30 June 2014, MorphoSys's liquid funds, marketable securities and financial assets amounted to EUR 374.2 million (31 December 2013: EUR 390.7 million).
PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Johnson & Weaver, LLP Reminds Investors of Upcoming September 16, 2014 Deadline; Encourages Investors with Significant Losses to Contact the Firm
Business Wire - Sat Jul 26, 3:06PM CDT
Shareholder rights law firm Johnson & Weaver, LLP reminds investors of the September 16, 2014 lead plaintiff deadline in a securities class action lawsuit filed by the firm against Prosensa Holding N.V. (NASDAQ:RNA). The class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of the class (the "Class"
. Those purchasers of the ordinary common shares of Prosensa pursuant and/or traceable to the Company's initial public offering ("IPO" on or about June 28, 2013 and suffered significant losses are encouraged to contact Johnson & Weaver regarding your legal rights. 
